Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

Advancements in the delivery of chimeric antigen receptor (CAR) T-cell therapy have led to a growing urgency to expand access across a range of care delivery settings.
The ACCC Eliminating Precision Medicine Disparities project is focused on understanding specific barriers and challenges to equal access to precision medicine among underserved patient communities.
ACCC's project is designed to engage all members of multidisciplinary cancer care teams as well as non-oncology specialists on effective practices for supporting, treating, and managing patients with advanced non-melanoma skin cancer.
The Roadmap will give users information about how to lay the groundwork for biosimilars, train and prepare their care team to offer biosimilars, implement biosimilars, and evaluate ongoing progress.
By highlighting best practices and sharing written guidelines, ACCC hopes that when BsAbs therapy for solid tumors becomes available, care providers will feel confident administering the treatment in community and rural cancer programs.
The ACCC Multidisciplinary Advanced Cutaneous Squamous Cell Carcinoma (cSCC) Care education project series is designed to support the cancer care team in diagnosing, testing, and treating patients with advanced cSCC.
ACCC will identify and disseminate examples of effective practices and tools for developing, implementing, and assessing operational pathways for molecular testing for eligible patients with non-small cell lung cancer.
This project will help the cancer care team enhance coordination of patient care and gain deeper knowledge, skills, and competence in biomarker testing practices, treatment selection, and management of adverse events in patients with advanced NSCLC.
To help facilitate the education and training that new treatment options often require, ACCC has created the Oncology Practice Transformation and Integration Center (OPTIC).
This project aims to help community cancer programs and practices of all sizes acquire the education and tools they need to offer CAR T-cell therapy close to where their patients live.
ACCC has launched an education project that is exploring the current state of MCED tests to develop best practices that cancer programs can adopt to fully integrate these tests as they become available.
CAR T-Cell Therapy Resource Library Optimize care coordination through the complex stages of CAR T-cell therapy with this comprehensive resource bank of curated, nationally available materials for the multidisciplinary care team. Discover expert insights, articles, videos, and practical tools focused on transitions of care before, during, and after CAR T-cell therapy that can help care teams improve …
ACCC aims to better understand patient and caregiver education and experience with CAR T-cell therapy.
To help facilitate the education and training that new treatment options often require, ACCC has created the Oncology Practice Transformation and Integration Center (OPTIC).
The Biosimilars Implementation Roadmap is an innovative learning tool that can help multidisciplinary cancer care teams obtain the knowledge they need to implement, expand, and sustain biosimilars as a treatment option for patients with cancer.
Dr. Nima Nabavizadeh MD is Associate Professor of radiation medicine, Program Director of the Radiation Oncology Residency Program for the Department of Radiation Medicine and Director of the Cancer Early Detection Clinical Research at CEDAR. Through partnerships with many biotech companies, Dr. Nabavizadeh studies the testing and implementation of novel tests for the early development of cancers. …
ACCC's project is designed to engage all members of multidisciplinary cancer care teams as well as non-oncology specialists on effective practices for supporting, treating, and managing patients with advanced non-melanoma skin cancer.
The aim of this project is to reframe the conversation between patients and providers to incorporate new therapy advancements, set expectations with patients about their treatment journey, and give them more confidence that there is new hope.
As B-cell ALL was the first disease state with an FDA-approved treatment for MRD, this project helps lay the foundation for MRD testing in patients with B-cell ALL with an innovative Implementation Roadmap.
ACCC, with its project partner LUNGevity and support by AstraZeneca and Genentech, has launched an educational initiative to promote effective practices and processes to facilitate timely and comprehensive biomarker testing.